Results 51 to 60 of about 18,983 (198)

Development of a Novel Polyleucine‐Based Immunopotentiator for Subunit Vaccines Against Group A Streptococcus

open access: yesSmall, EarlyView.
Self‐assembling amphiphilic peptide L15K6 is used as a novel immunoadjuvant for the development of a Group A Streptococcus vaccine. Robust antigen‐specific IgG responses are generated and manage to kill isolated strains of Group A Streptococcus. Cellular and bulk RNA sequencing data reveals that L15K6 regulates immune responses potentially through TLR ...
Lantian Lu   +25 more
wiley   +1 more source

TRANSFORMATION OF CHRONIC MYELOMONOCYTIC LEUKEMIA TO ACUTE MONOCYTIC LEUKEMIA IN AN ELDERLY PATIENT: A CASE REPORT

open access: yesHematology, Transfusion and Cell Therapy
Introduction: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder that exhibits both myelodysplastic and myeloproliferative features. Progression to acute monocytic leukemia is a notable complication, especially in elderly patients.
AM Oba   +6 more
doaj   +1 more source

The effects of photodynamic therapy on leukemia cells mediated by KillerRed, a genetically encoded fluorescent protein photosensitizer

open access: yesBMC Cancer, 2019
Background Leukemia is a cancer of blood and bone marrow cells, causing about 300,000 deaths worldwide. Photodynamic therapy (PDT) is a promising alternative for the treatment of malignant tumors.
Meng Yuan   +6 more
doaj   +1 more source

Securinine, a myeloid differentiation agent with therapeutic potential for AML. [PDF]

open access: yesPLoS ONE, 2011
As the defining feature of Acute Myeloid Leukemia (AML) is a maturation arrest, a highly desirable therapeutic strategy is to induce leukemic cell maturation. This therapeutic strategy has the potential of avoiding the significant side effects that occur
Kalpana Gupta   +8 more
doaj   +1 more source

Acute Monocytic Leukaemia with Cutaneous Manifestation

open access: yesJournal of Cutaneous Pathology, 2005
A 50‐year‐old Caucasian male presented with generalised skin rash. Gingival hyperplasia and hepatosplenomegaly were also noted. His laboratory data showed hemoglobin of 10.3 g/dL, white blood cell count of 203.6 K/uL and platelet count of 72 K/uL. Peripheral blood smears revealed that 67% of the white blood cells was monoblasts, 25% was promonocytes ...
Leilei, Chen   +3 more
openaire   +2 more sources

Photo‐induced proton release of spiropyran‐derived nanomaterials for mRNA delivery in hard‐to‐transfect cells

open access: yesSmart Molecules, EarlyView.
Light‐induced proton release from spiropyran can disrupt the stability of both nanoparticles and endosomal membranes, thereby promoting endosomal escape and ultimately enhancing transfection performance. Abstract Messenger RNA (mRNA) therapy has been explored as a treatment for various genetic disorders. Significant progress has been made in developing
Caiwei Lu   +6 more
wiley   +1 more source

B-cell acute lymphoblastic leukemia with t(4;11)(q21;q23) in a young woman: evolution into mixed phenotype acute leukemia with additional chromosomal aberrations in the course of therapy

open access: yesHematology Reports, 2012
About 5% of adult B-cell acute lymphoblastic leukemias (B-ALL) are characterized by t(4;11)(q21;q23), which confers peculiar features to this B-ALL subtype, including a very immature immunophenotype and poor prognosis.
Giovanni Carulli   +8 more
doaj   +1 more source

Solamargine induces acute myeloid leukemia differentiation through TLR8 activation

open access: yesVIEW, EarlyView.
SM, a steroidal alkaloid from Solanum nigrum L. has shown anticancer effect on various kinds of human cancer cells, yet its effect on leukemia cells remains unclear. This study examines antileukemic activities of SM in AML cells. Results indicate SM inhibits growth and promotes apoptosis of AML cells.
Qiaoyan Han   +11 more
wiley   +1 more source

Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells

open access: yesHaematologica, 2020
Combination treatment has proven effective for patients with acute promyelocytic leukemia, exemplifying the importance of therapy targeting multiple components of oncogenic regulation for a successful outcome. However, recent studies have shown that the
Simon Hultmark   +12 more
doaj   +1 more source

Targeting MCL‐1 and MAPK overcomes venetoclax resistance in FLT3‐ITD‐positive AML cells harbouring activating PTPN11 (SHP‐2) mutations

open access: yesBritish Journal of Haematology, EarlyView.
Summary Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients ...
Maximilian Fleischmann   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy